According to TheraGenetics, the strategic expansion into the area of depression underscores the company’s commitment to licensing new technologies to build a foundation for future diagnostic tests for the most common central nervous system conditions. Centre for Addiction and Mental Health (CAMH) is said to share TheraGenetics’s commitment to improving patient care and treatment.
Richard Kivel, CEO of TheraGenetics, said: “The intellectual property we licensed from CAMH further augments our capabilities to innovate pharmacogenetic diagnostics tests in a broad range of disorders, including schizophrenia, depression, bipolar disorder, Alzheimer’s disease and attention-deficit hyperactivity disorder.”